Didier Mayeur

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

Xavier Pivot, Gilles Romieu, Marc Debled et al. · The Lancet · 2019 · 128 citations

Medicine, Oncology, Breast Oncology +9

Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. Subcutaneous Administration Propeukin Program Cooperative Group.

J.M. Tourani, C. Pfister, J.F. Berdah et al. · Journal of Clinical Oncology · 1998 · 78 citations

Medicine, Oncology, Pharmacotherapy +17

Symptomatic Treatment With Lanreotide Microparticles in Inoperable Bowel Obstruction Resulting From Peritoneal Carcinomatosis: A Randomized, Double-Blind, Placebo-Controlled Phase III Study

Pascale Mariani, Joëlle Blumberg, Alain Landau et al. · Journal of Clinical Oncology · 2012 · 59 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Extended Anticoagulant Treatment with Full- or Reduced-Dose Apixaban in Patients with Cancer-Associated Venous Thromboembolism: Rationale and Design of the API-CAT Study

Isabelle Mahé, Giancarlo Agnelli, Cihan Ay et al. · Thrombosis and Haemostasis · 2021 · 59 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17